Journal: Avicenna Journal of Medical Biotechnology

Article Title: An Anti-TAZ Monoclonal Antibody Recognizing Cell Surface Expressed TAZ Protein in Human Tumor Cells

doi: 10.18502/ajmb.v15i1.11420

Figure Lengend Snippet: Reactivity of 1F3 with cell surface TAZ on membranes of Burkitt's lymphoma, breast cancer and squamous cell carcinoma lines using flow cytometry technique. Values demonstrate the percentages of positive cells. 1F3 detected cell surface expression of TAZ in pathological conditions with no reactivity in normal conditions. Anti-TAZ mAb was applied on: A) A431, B) MCF-7, C) Raji D) HFFF-PI6 E) MDA-MB-231 G) Normal PBMC (anti-TAZ mAb) and anti-TAZ pAb was used on F) A431 (commercial pAb anti TAZ).

Article Snippet: To evaluate the localization of TAZ protein, flow cytometry analysis was performed both at intracellular and cell surface staining using both produced anti-TAZ mAb and polyclonal anti-TAZ antibody (Abcam).

Techniques: Flow Cytometry, Expressing

Journal: BMC Bioinformatics

Article Title: A methodology for exploring biomarker – phenotype associations: application to flow cytometry data and systemic sclerosis clinical manifestations

doi: 10.1186/s12859-015-0722-x

Figure Lengend Snippet: Example random walk. Gene Set Enrichment Analysis random walk for a flow cytometry set comprised of 27 variables

Article Snippet: The methods utilized in the work involve: (1) clinical and peripheral blood flow cytometry data ( I mmune R esponse I n S cleroderma, IRIS) from consented patients followed at the Johns Hopkins Scleroderma Center. (2) machine learning (Conditional Random Forests - CRF) coupled with Gene Set Enrichment Analysis (GSEA) to identify subsets of FC variables that are highly effective in classifying ILD patients; and (3) stochastic simulation to design, train and validate ILD risk screening tools.

Techniques: Flow Cytometry

Journal: Frontiers in Immunology

Article Title: Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4 + T cell immunity within the FLUCOP consortium

doi: 10.3389/fimmu.2022.982887

Figure Lengend Snippet: Parameters selected for the ICS consensus assay.

Article Snippet: Eight laboratories participated in pilot study 2 and provided data of their analysis of the flow cytometry data for IFNγ and polypositive CD4 + and CD8 + T cells ( ).

Techniques: Cell Counting, Staining

Journal: Frontiers in Immunology

Article Title: Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4 + T cell immunity within the FLUCOP consortium

doi: 10.3389/fimmu.2022.982887

Figure Lengend Snippet: Pilot Study 2: Variability of post-analytical analysis between laboratories. Eight laboratories participated in pilot study 2. Each laboratory analyzed fcs files from 10 unstimulated (background) and 10 stimulated samples (x-axis). Each dot represents the number of Ag-specific live IFNγ or polypositive CD4 + or CD8 + cells per million parent cells from one laboratory. The horizontal line with error bars indicate the mean +/- standard deviation per sample. IFN, interferon; PP, polypositive.

Article Snippet: Eight laboratories participated in pilot study 2 and provided data of their analysis of the flow cytometry data for IFNγ and polypositive CD4 + and CD8 + T cells ( ).

Techniques: Standard Deviation

Journal: Frontiers in Immunology

Article Title: Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4 + T cell immunity within the FLUCOP consortium

doi: 10.3389/fimmu.2022.982887

Figure Lengend Snippet: Pilot Study 2: Gating practices for cytokine secreting CD4 + T cells from each of the participating laboratories, and examples of a single cytokine gate (IFNγ) from each of the laboratories Eight laboratories participated in pilot study 2-, gating strategy did not show single IFNγ-secreting cells; IFN, interferon.

Article Snippet: Eight laboratories participated in pilot study 2 and provided data of their analysis of the flow cytometry data for IFNγ and polypositive CD4 + and CD8 + T cells ( ).

Techniques: